Electrocardiographic effects of HBI-3000 (sulcardine sulfate), a new drug for termination of atrial fibrillation

Sulcardine increased the QTc and PR intervals, QRS and P-wave durations, and HR dose dependently. The T-wave segment JTpc was significantly decreased, whereas the T peak to T end interval was significantly increased. These findings predict an anti-atrial fibrillation effect via inhibition of 1 or more cardiac ion channels. The strong block of the rapid component of the delayed rectifier potassium channel current was partially mitigated by JTp shortening, probably owing to late sodium current and L-type calcium current inhibition, reducing the risk of proarrhythmia by decreasing repolarization time.

Authors

Institutions

Publication Details

Journal
Heart Rhythm O2
Published
2026-01-02
DOI
https://doi.org/10.1016/j.hroo.2025.11.019
Primary Topic
Cardiac electrophysiology and arrhythmias
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Electrocardiographic effects of HBI-3000 (sulcardine sulfate), a new drug for termination of atrial fibrillation

Stephanie H. Stanworth, Jerome B. Riebman, Suzanne J. Romano, Jay W. Mason et al.
Heart Rhythm O2
Cardiac electrophysiology and arrhythmias
article

Electrocardiographic effects of HBI-3000 (sulcardine sulfate), a new drug for termination of atrial fibrillation

Stephanie H. Stanworth, Jerome B. Riebman, Suzanne J. Romano, Jay W. Mason, Boaz Mendzelevski, Gary Elliott, Fabio Badilini, Martino Vaglio, Mireille Gillings
article en

Abstract

Sulcardine increased the QTc and PR intervals, QRS and P-wave durations, and HR dose dependently. The T-wave segment JTpc was significantly decreased, whereas the T peak to T end interval was significantly increased. These findings predict an anti-atrial fibrillation effect via inhibition of 1 or more cardiac ion channels. The strong block of the rapid component of the delayed rectifier potassium channel current was partially mitigated by JTp shortening, probably owing to late sodium current and L-type calcium current inhibition, reducing the risk of proarrhythmia by decreasing repolarization time.

Heart Rhythm O2Vol. 7(2)
University of Utah (US), Galena Biopharma (United States) (US), ISCO International (United States) (US), Cambridge Consultants (United Kingdom) (GB), Stantec (Canada) (CA)
Good health and well-being
Openalex Percentile: Top 99%
Cardiac electrophysiology and arrhythmias
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Electrocardiographic effects of HBI-3000 (sulcardine sulfate), a new drug for termination of atrial fibrillation — Stephanie H. Stanworth, Jerome B. Riebman, et al. · Heart Rhythm O2 (2026) | TGRS Research Map | TGRS